Prediction of PPC Using DAMPs in Adult Cardiac Surgery
Prediction of Postoperative Pulmonary Complications Using Damage-associated Molecular Patterns in Adult Cardiac Surgery
1 other identifier
observational
53
1 country
1
Brief Summary
DAMPs (damage associated molecular patterns) are endogenous molecules that are expressed by cell stress or cell damage and play an important role in tissue (or host) defense and repair by activating the innate immune system. This is not the case with infections or injuries. Briefly, it starts when the immune system is activated by a receptor that recognizes a damage pattern, and it is a generic term for continuous responses by endogenous molecules expressed in this process. Recently, immuno-cancer drugs for cancer treatment by applying this immune response are also emerging. In cardiac surgery using cardiopulmonary bypass (CPB), there are more deleterious effects and adverse effects caused by using CPB than the surgery itself. There are several studies that have revealed the association between DAMPs and the degree of complications by approaching them from the point of view of tissue damage caused by the use of CPB. Therefore, we intend to investigate the changes in DMAPs over time during, and after cardiac surgery and the differences in DAMPs according to the presence or absence of postoperative pulmonary complications.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Aug 2018
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 6, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 30, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
March 30, 2020
CompletedFirst Submitted
Initial submission to the registry
June 16, 2021
CompletedFirst Posted
Study publicly available on registry
June 30, 2021
CompletedOctober 17, 2023
October 1, 2023
1.6 years
June 16, 2021
October 14, 2023
Conditions
Outcome Measures
Primary Outcomes (2)
Concentration of heparan sulfate (HS)
blood sampling before CPB application, 90 minutes after CPB application, after CPB weaning, the day after surgery
the day after surgery, up to 48hours
Concentration of high mobility group box 1 (HMGB1)
blood sampling before CPB application, 90 minutes after CPB application, after CPB weaning, the day after surgery
the day after surgery, up to 48hours
Secondary Outcomes (1)
Postoperative complication
during admission, up to 22 days
Interventions
There was no intervention because this reasearch is observational study.
Eligibility Criteria
Patients undergoing cardiac surgery using cardiopulmonary bypass (CPB)
You may qualify if:
- Adult patients over 20 years of age
- Patients undergoing cardiac surgery using cardiopulmonary bypass (CPB)
You may not qualify if:
- pregnant women and minors
- the patients who required mechanical life support as follows due to unstable vital signs after CPB weaning, ECMO (extracorporeal membrane oxygenation) IABP (intra-aortic balloon pump)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Pusan National University Yangsan Hospital
Yangsan, South Korea
Biospecimen
Blood samples were collected four times in total, and 7 ml of blood was collected after induction of anesthesia (T1), 90 minutes after CPB (T2), immediately after weaning from CPB (T3), and on the first day after surgery (T4). It was placed in a serum-separating tube and then centrifuged. Enzyme-linked immune sorbent assay is performed to measure the concentration of heparan sulfate (HS) and high mobility group box 1 (HMGB1) using HS ELISA kit (Finetest, EH4010) and HMGB1 ELISA kit (Solarbio, SEKH-0409), respectively. use.
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Hee Young Kim, MD, PhD
Pusan National University Yangsan Hospital
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Clinical associate professor
Study Record Dates
First Submitted
June 16, 2021
First Posted
June 30, 2021
Study Start
August 6, 2018
Primary Completion
March 30, 2020
Study Completion
March 30, 2020
Last Updated
October 17, 2023
Record last verified: 2023-10